Anke Biotech executive plans share sale for personal funding

Anhui Anke Biotechnology Group announced that senior executive Yao Jianping plans to sell up to 1 million shares, representing 0.06% of its total share capital. As of the announcement date, Yao Jianping holds 6,762,235 shares, or 0.40% of the total share capital. The share reduction is attributed to personal funding needs.

The planned disposal will occur within a three-month period, from September 26, 2025, to December 25, 2025, following a 15-trading-day window from the announcement date. The sales will be conducted through centralized bidding or block trading. The company confirmed that Yao Jianping has fulfilled all prior commitments regarding share restrictions and that the planned sale complies with relevant regulations.

The company will monitor the progress of the share reduction and ensure timely information disclosure. Investors are advised to exercise caution, as the timing, volume, and price of the share reduction are subject to market conditions and the company's stock price fluctuations. The proposed sale will not result in a change of control of the company.